Our unique approach leverages deep scientific knowledge of medical dermatology to
identify ‘de-risked’ opportunities to improve patients’ lives
Developing and commercialising
medicines for dermatology diseases with
major unmet needs
ALOPECIA AREATA
characterised by non-scarring hair loss on the scalp and body.
This currently represents a major under-served area of dermatology - particularly for patients with mild-moderate (patchy) disease:
-
No approved therapies for mild-moderate alopecia areata, and yet the disease
burden is as significant as patients with severe disease - 800,000 patients in the US, of which at least 50% are mild-moderate ‘patchy’ AA sufferers
- Recognised by the FDA as a debilitating condition and a priority for new therapies, across all severities
STS-01
completes Phase II trial for mild / moderate alopecia areata.
STS-01 is being developed to address the need for an effective, safe and convenient non-steroidal topical therapy for patients with mild-moderate (patchy) alopecia areata.
The product builds on a mechanism with a well established safety profile in dermatology, and existing evidence of efficacy in this indication through targeting key relevant cytokines. STS-01 has been modified to maximise the efficacy of this mechanism, and offer a cosmetically elegant topical cream.
Whilst the JAK inhibitors have the potential to offer a new treatment option for severe patients, their use more broadly will be limited by concerns with their side effect profiles (and price).
STS-01 has announced positive topline data from its 158-patient Phase-II study.
LINK TO PRESS RELEASE